Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Infections

Rare Diseases

Ulcer

Stomach Neoplasms

Gallstones

Cholelithiasis

Cholecystolithiasis

Appendicitis

Stomach Ulcer

Gastrointestinal Diseases

Stomach Diseases

Intestinal Diseases

Communicable Diseases

Intraabdominal Infections

Gastroenteritis

Cecal Diseases

Peptic Ulcer

Duodenal Diseases

Biliary Tract Diseases

Gallbladder Diseases

Calculi

Pathological Conditions, Anatomical

Stomach Cancer

20-70 patients undergo Micro Hand S robotic surgeries

Micro Hand S robotic surgery

20-70 patients undergo laparoscopic surgeries

laparoscopic surgery

20-70 patients undergo da Vinci robotic surgeries

da Vinci robotic surgery

shaihong zhu, MD

Central South University in collaboration with Tianjin University developed the first domestically produced Chinese minimally invasive surgical (MIS) robot system which named "Micro Hand S" in 2013. Recently, as the domestic surgical robot research project's main section, this new MIS robot had been authorized to enter the clinical trial stage by the Ethics Committee of the Third Xiangya Hospital at Central South University.

One surgeon perform these surgical trials using the robot "Micro Hand S". All of the patients were followed for 12 months, and pre- and postoperative changes in blood route test and hepatorenal function examination, surgery duration, hospital stay, total robotic setup time, total robotic operation time, intraoperative blood loss, total postoperative drainage amount, duration of bearing drainage tubes were recorded. In addition, the pre- and postoperative changes in the pathological and functional outcomes were measured.

Domestic Surgical Robot Clinical Study

Safety and Feasible Study of Domestic Surgical Robot That Had Been Authorized to Enter the Clinical Trial Stage

surgical procedure/operative time/console time/blood loss/conversion

Time to first flatus/intake/hospital stay

resection margin/harvested lymph node/mesorectal grade

type of complication/grade of complication

The Third Xiangya Hospital of Central South University

Nutritional and Metabolic Diseases

Syndrome

Carcinoma

Obesity

Metabolic Syndrome

Carcinoma, Hepatocellular

Obesity, Morbid

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Insulin Resistance

Hyperinsulinism

Metabolic Diseases

Glucose Metabolism Disorders

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

Patients aged 18 years old and older, affected by HCC with MS (metabolic syndrome) as unique risk factor who comply with the criteria for bariatric surgery, will undergo liver resection and sleeve gastrectomy with minimally-invasive technique in the same surgical procedure

Patients aged 18 years old and older, affected by HCC (hepatocellular carcinoma) with MS (metabolic syndrome) as unique risk factor who will undergo liver resection only

Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.

Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome

Patients in the active comparator arm will undergo liver resection for HCC

Liver resection for HCC induced by metabolic syndrome

Annarita Libia

Hepatocellular carcinoma (HCC) related to metabolic syndrome (MS) as unique risk factor is gradually overpassing the more common viral and alcohol etiology, becoming a global health issue. Liver surgery for metabolic syndrome-related HCC in this frail subset of patients constitute a challenge, due to high morbidity and mortality rate reported in literature, and contrasting results in term of oncologic outcome. The present multicentric prospective study aims to ascertain if the combination of sleeve gastrectomy and liver surgery in the same surgical procedure may have benefit in terms of reduced perioperative morbidity and prolonged Overall Survival and Recurrence Free Survival. Secondary outcome will be the evaluation of the consequences induced by sleeve gastrectomy on liver disease, in particular liver fibrosis evaluated in term of NFS score (Non-Alcoholic Fatty Liver Disease Fibrosis score), FIB-4 (Fibrosis-4 Index for Liver Fibrosis) score and Fibroscan transient elastography.

Obesity is a worldwide epidemic, with more than 2 billion people currently overweight and an additional 1.12 billion projected to be overweight by 2030. HCC (hepatocellular carcinoma) associated to obesity and its comorbidity is overcoming Hepatitis C Virus (HCV) related cancer and is already the leading cause of liver transplant in USA. HCC remains the sixth most common cancer in the world and the third cause of cancer-related death. Considering these epidemiological evidence, the incidence of MS-HCC (metabolic syndrome-related hepatocellular carcinoma) is expected to increase with huge cost efforts for the global healthcare system. The impaired performance status of patients with HCC and metabolic syndrome seems to explain high perioperative morbidity rate reported in literature. Literature reports several experiences of bariatric surgery combined to liver transplant for chronic liver disease related induced by non alcoholic steatohepatitis (NASH), performed before or after liver surgery, or even at the same time. Even if evidences are weak, outcomes reported seem to be promising. Since sleeve gastrectomy is not only a mere restrictive bariatric procedure, but it produces hormonal and metabolic changes, with the present study the investigators want to ascertain if sleeve gastrectomy at time of liver resection for MS-HCC (metabolic syndrome-related hepatocellular carcinoma) can modify short perioperative outcomes and long-term oncologic results.

Patients 18 years old and older, affected by hepatocellular carcinoma (HCC) with metabolic syndrome (MS) as unique risk factor, with compensated liver function (Child A) who are deemed suitable for liver resection and comply with the criteria for bariatric surgery, will undergo liver resection of HCC and simultaneous sleeve gastrectomy for morbid obesity during the same surgical procedure.

Patients affected by HCC related to metabolic syndrome who fall within exclusion criteria, will undergo liver resection for HCC without sleeve gastrectomy.

Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)

Liver Resection and Simultaneous Sleeve Gastrectomy for HCC Related to Metabolic Syndrome (LIRESS)

Calculated from the date of diagnosis to the date of death from any cause

Calculated from the date of surgery to the date of recurrence

Any deviation from the normal postoperative course measured on a scale from 0 (no complication) to 100 (death)

Fibrosis-4 Index for Liver Fibrosis score (FIB-4 score) will be calculated using the following formula:

FIB-4 score= Age (years)× aspartate aminotransferase (AST) (U/L)/\[platelet count (109/L)×√alanine aminotransferase (ALT) (U/L)\]

Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS score) will be calculated using the following formula:

NFS = -1.675 + 0.037 - age (years) + 0.094 - BMI (kg/m2) + 1.13 × impaired fasting glucose/diabetes (yes = 1, no = 0) + 0.99 × aspartate aminotransferase/ alanine aminotransferase (AST/ALT) ratio - 0.013 × platelet count (×109/l) - 0.66 × albumin (g/dl).

The Fibroscan stiffness measurement relies on the propagation of elastic waves to assess the stiffness of the liver: the faster elastic waves propagates within the liver, the stiffer the organ is. The final liver stiffness value is the median of individual liver stiffness values using the valid measurements and is expressed in kilo Pascal (kPa).

Body Mass Index (BMI) is combination of bodyweight and body height and presented as kg/m\^2

Percent excess weight loss (%EWL) is calculated as follows: \[(initial weight - current weight) / (initial weight - ideal weight)\] × 100

Change of antihypertensive therapy assessed by medical history questionnaire

change of insulin therapy or oral hypoglycemics assessed by medical history questionnaire

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Domestic Surgical Robot Clinical Study	NCT02752698	Gastric Ulcer W... Colon Cancer Cholecystolithi... Appendicitis Sleeve Gastrect... Gastric Bypass Gastric Cancer Rectal Cancer	Micro Hand S ro... laparoscopic su... da Vinci roboti...	18 Years - 80 Years	The Third Xiangya Hospital of Central South University
Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)	NCT06060847	Carcinoma, Hepa... Metabolic Syndr...	Liver resection... Liver resection...	18 Years -	Ospedale V. Fazzi
Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)	NCT06060847	Carcinoma, Hepa... Metabolic Syndr...	Liver resection... Liver resection...	18 Years -	Ospedale V. Fazzi

Spots Global Cancer Trial Database for sleeve gastrectomy